Navigation Links
GenSpera to Present at Rodman & Renshaw 16th Annual Global Investment Conference

SAN ANTONIO, Aug. 14, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference. The conference will be held September 8-10, 2014 at the New York Palace Hotel in New York.

The conference is attended by public companies, institutional investors, sophisticated private investors and industry executives.

GenSpera will be presenting at 12:05 pm Tuesday, September 9th. The Company will discuss the significance of the recently announced HCC clinical trial update for G-202, its lead drug candidate, as well as provide a corporate overview. The company has released interim results from the Phase Ib and ongoing Phase II study in hepatocellular carcinoma (HCC) patients who had previously progressed on, or who were intolerant of sorafenib ( Nexavar®, a drug co-developed and co-marketed by Bayer and Onyx Pharmaceuticals, an Amgen subsidiary).  Impressively, 80% of patients treated with G-202 had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at 4 months on study. In addition, imaging analysis demonstrated impressive blockade of tumor blood flow in the single patient evaluated by this method to date.

Hepatocellular carcinoma (HCC) is currently the sixth most common malignancy in the world and the third leading cause of cancer-related mortality worldwide.

Craig Dionne, PhD, GenSpera's CEO said of the pending conference," I am excited to share the recent data and results for G-202 and its efficacy and safety analyses on patients to date. G-202 has potential to treat multiple cancers including prostate cancer and glioblastoma but our primary focus is currently hepatocellular carcinoma (HCC). The liver cancer data we recently presented at APPLE and other scientific conferences was overwhelmingly embraced by our peers; now this conference creates an opportunity to explain the significance and the promise it holds to the investment community."

About the conference:

About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.

G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.

For more information, please visit the company's website: or follow us on Twitter @GenSperaNews.

Company presentations are available at:

Watch the Corporate Video:

Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.


Craig Dionne, PhD, CEO
GenSpera, Inc.  (210) 479-8112

Steve Gersten
Capital Markets Group

Dawn Van Zant
(800) 665 0411

SOURCE GenSpera, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. GenSpera Presents G-202 HCC Clinical Trial Update at 5th Asia-Pacific Primary Liver Cancer Expert Meeting
2. Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation
3. Aventura Client Presents Enhancing Emergency Department Documentation Efficiency at Optum Client Forum 2014
4. Lpath to Present at 34th Annual Canaccord Genuity Growth Conference
5. Genomic Health to Present at the Canaccord Genuity 34th Annual Growth Conference
6. Lexicon To Present At The 2014 Wedbush Life Sciences Management Access Conference
7. Omeros to Present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference
8. Guardant Health to Present at the WedBush 2014 Life Sciences Management Access Conference
9. Mast Therapeutics To Present At The Canaccord Genuity 34th Annual Growth Conference On August 14th
10. STAAR Surgical To Present At Wedbush And Canaccord Investor Conferences
11. KemPharm, Inc. to Present at the Canaccord Genuity 34th Annual Growth Conference
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015 NHS Supply ... 20 TrueBeam™ machines from Varian Medical Systems (NYSE: ... program to replace older machines and institute modern ... UK,s public hospitals. The order, placed in September, ... licenses for Varian,s RapidArc® and Eclipse™ software systems.    ...
(Date:11/30/2015)... , Nov. 30, 2015  Hanger, Inc. (NYSE: ... restatement of the terms of its previously announced consent ... to its $200,000,000 aggregate principal amount 7⅛% Senior Notes ... (i) the consent fees payable pursuant to the Consent ... Notes and (iii) the expiration date of the Consent ...
(Date:11/30/2015)... , Nov. 30, 2015  Precision Image ... services, is pleased to announce a dramatic expansion ... imaging services. Building on its ISO-9001:2008 certification for ... implemented comprehensive Core Lab protocols and procedures. This ... of research activities.  Their Core Lab services include ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... Center is one of a select few plastic surgeons in the New York ... removal. , SculpSure™ is the world’s first heat-induced laser treatment for fat loss ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... TransPack Volume ... X . Choose from scrolling web-styled transitions to wipes with blur & drop ... direction and more. Seamlessly transition from one clip to the next with TransPack's ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... their strategic partnership at the Radiological Society of North America (RSNA) 2015 ... global providers of cutting-edge dictation and speech-enabled documentation software, announced their partnership ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... In 2016, expected coding changes are likely to include new codes for spine ... not easy to understand the effects of code changes in musculoskeletal, radiology and ...
(Date:11/30/2015)... ... 30, 2015 , ... CTI Group (Holdings) Inc. (OTC:CTIG), a ... communication analytics, announced today that their Proteus® VoIP QMS solution now supports Skype ... Proteus® VoIP QMS (Quality Management System) does this by collecting the ...
Breaking Medicine News(10 mins):